The fully connected environment, digital technologies and artificial intelligence tools enable optimization of patient care.
JENA, Germany and DUBLIN, Aug. 30, 2022 /PRNewswire/ -- ZEISS Medical Technology continues to build on its leadership in digital solutions by exploring new ways to advance the future of transformative care in ophthalmology. At ZEISS Innovation Week, September 6-8, 2022, ZEISS Medical Technology will host leading experts in ophthalmology to share their personal experiences of how the power of integrated workflow solutions, data management and a range of new software applications are enabling improved efficiencies and optimization of patient care.
ZEISS will also exhibit at the European Society of Cataract and Refractive Surgeons (ESCRS) Annual Meeting, September 16-20, and the American Academy of Ophthalmology (AAO) Conference, Sept. 30 - Oct. 3, providing demos, educational programs, and scientific events discussing how digital technologies can promote clinical efficiency and improved patient outcomes.
"As a leader in digital solutions, ZEISS is setting the standard for new ways to manage care at scale. Using data insights and integrated workflow solutions with artificial intelligence adds value in managing disease progression and the optimization of clinical practices," said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of Digital Business at Carl Zeiss Meditec, Inc. "We continue to focus on the development of digital solutions creating the roadmap needed for improved care."
"The digital workflow is the backbone of a practice because it integrates all the diagnostics, the therapeutics, gives peace of mind and less stress to the clinician and the surgeon," said Sri Ganesh, MD, Chairman and Managing Director of Nethradhama Hospital, India. "At the end of the day, that is what you want to see - efficiency, safety, more patients that can be accommodated and better results."
"Our workflow is completely integrated, we're 100 percent paperless, and everything talks to each other," said Bruce A. Rivers, MD, Envue Eye & Laser Center, Maryland, U.S. "The benefits of this integrated workflow are a happy staff, less work for everybody involved, and everything flows a lot easier, decreasing time, stress, and ultimately improving the patient experience."
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,290 employees worldwide, the Group generated revenue of 1,335.5m in fiscal year 2019/20 (as of 30 September 2020).
The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med
SOURCE Carl Zeiss Meditec AG